



Open and Endovascular Treatment of Superior Vena Cava Syndrome of Benign Etiology

George Geroulakos, Professor of Vascular Surgery

Chairman of Department of Vascular Surgery, Attikon University Hospital, Athens









Background

- The increased use of central venous catheters, ports, pacemakers and defibrillators raised the incidence of benign superior vena cava syndrome (SVCS)
- 19.000 cases of SVCS occur every year in the United States
- Benign aetiologies may now comprise up to 40% of cases

Types of SVCS






Type I Type II

Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg 1986;41:158-63.



Αγγειοχειρουργική Κλινική Ιατρικής Σχολής Πανεπιστημίου Αθηνών Π.Γ.Ν. "Αττικόν"

Types of SVCS



Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg 1986;41:158-63.




Αγγειοχειρουργική Κλινική Ιατρικής Σχολής Πανεπιστημίου Αθηνών Π.Γ.Ν. "Αττικόν"

Open and Endovascular Treatment of SVCS of Benign Etiology

"endovascular"[All Fields] OR
"open"[All Fields]

AND "vena cava"[All Fields]

AND ("thrombosis"[All Fields]
OR "occlusion"[All Fields])





- 9 studies (all retrospective): 136 patients
 - Central venous catheters and pacemakers 80.6%
 - Mediastinal fibrosis 13.7%
 - Other causes 5.6%
 - Post radiation fibrosis
 - Benign tumor
 - Goiter
 - Transposition of the great vessels


Risk Factors

- History of DVT
- Neck irradiation
- Behcet disease
- Existing dialysis fistula on the side of pacemaker leads

Diagnosis

- Earlier venography
- Later CT venography or MR venography

Types of SVCS



Type I 6.6%

Type II 37.7%

Type III 42.2%

Type IV **13.3%**



Technical success 95.6% (132/138)

- PTA + stenting 73.6%
- PTA 17.3%
- Thrombolysis, PTA and stenting 9%

Stents

Self expanding

- Wallstent (Boston Scientific) 53.7%
- S.M.A.R.T (Cordis) 8.7%
- Protégé (eV3 Inc) 5%
- Zilver (Cook), Luminexx (Bard)1.2%

Balloon expandable

- Palmaz (Cordis) 20%
- Express LD (Boston Scientific) 2.5%
 Gianturco Z stent 1.2%

Covered stents

- Viabahn (W.L. Gore) 3.7%
- iCast (Atrium Maquet) 1.2%

Pacemaker-Induced SVCS

Two Techniques

- 1.Lead removal, stent implantation, and reimplantation of new leads
- 2.Plain balloon dilatation of the vein with stent placement in selected cases

Results

30- day mortality 0%

- Complications 3.6%
 - Stent migration (2 patients)
 - SVC penetration
 - Arm hematoma
 - 3rd degree heart block

Results


- FU 11-48 months
- Regression of the symptoms: 97.3%
- Recurrence 32 pts (26.6%)
- 58 secondary procedures
 - 48 PTAs
 - 5 PTAs with stenting
 - 3 thrombolyses and
 - 2 bypass grafts


- 4 studies (all retrospective): 87 patients
 - Central venous catheters and pacemakers 28.5%
 - Mediastinal fibrosis 58.4%
 - Other causes 13%
 - 5 idiopathic thromboses
 - 2 hypercoagulable state
 - 2 after ventriculoatrial shunts
 - 1 surgical excision


Types of SVCS


Right

vein









Type I 9.8%

Type II 11.5%

Type III 34.4%

Type IV 44.2%





Αγγειοχειρουργική Κλινική Ιατρικής Σχολής Πανεπιστημίου Αθηνών Π.Γ.Ν. "Αττικόν"

Type of graft

- Spiral saphenous vein graft 59.7% (52/87)
 - ✓ Straight (48/52): Innominate or Jugular vein to right atrial appendage
 - ✓ Bifurcated (4/52): Internal jugular vein and innominate vein to right atrial appendage
- **Externally reinforced ePTFE** 26.4% (23/87)
- Femoral vein 6.8% (6/87)
- **Human allograft** 2.3% (2/87)
- Reversed saphenous vein 1.1% (1/87)
- Venous transposition 3.4% (3/87)







Results

• 30- day mortality 0%


- 13 reoperations (15%) before discharge
 - 8 graft thrombosis
 - 3 stenoses of the graft
 - 2 patients with a mediastinal hematoma needing evacuation

Results

- FU 30 m 10.9 years
- Complete or partial regression of the symptoms: 93.5%
- Recurrence 24 pts (31.1%)
 - 33 secondary procedures
 - 10 PTAs
 - 11 PTAs with stenting
 - 9 thrombectomies
 - 2 graft replacements
 - 1 thrombolysis



Pooled primary patency after endovascular and open surgical repair for benign SVC syndrome



Conclusions

 Benign SVCS syndrome is now more common as the use of indwelling catheters for dialysis and cardiac therapy expands

 Both open and endovascular treatments show good results regarding regression of the symptoms

 Mid-term primary patency is similar with a significant incidence of secondary interventions

Conclusions

- Endovascular is the first line of treatment for SVCS caused by intravenous devices, while surgery is most often performed for mediastinal fibrosis
- Patients who underwent surgical treatment usually presented with more severe disease
- There is a high incidence of reoperations before discharge after surgery
- Secondary interventions after initial endovascular treatment or open surgery are mainly endovascular

